Journal Scans
A High Response Rate to Liposomal Doxorubicin Is Seen Among Women With BRCA Mutations Treated for Recurrent Epithelial Ovarian Cancer
High Response to Doxil in BRCA-Mutated Ovarian Cancer
SF Adams, EB Marsh, W Elmasri, SC Rubin, et al
20111101
2011 Dec 1
Gynecol Oncol
A High Response Rate to Liposomal Doxorubicin Is Seen Among Women With BRCA Mutations Treated for Recurrent Epithelial Ovarian Cancer
Gynecol Oncol. 2011 Dec 1;123(3):486-491, SF Adams, EB Marsh, W Elmasri, SC Rubin, et al
TAKE-HOME MESSAGE
Abstract
Abstract
Objective: Ten percent of ovarian cancer is attributed to hereditary syndromes, most commonly to mutations in the BRCA1 or BRCA2 genes. These cancers are characterized by a prolonged sensitivity to platinum agents in spite of presentation at advanced stages. We hypothesized that women with BRCA-associated ovarian cancer would also show a high response rate to pegylated liposomal doxorubicin (Doxil).Methods: A retrospective cohort study was conducted to compare the response rate, progression-free,...
